Is Keflex (cephalexin) a highly bioavailable oral antibiotic in otherwise healthy adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Keflex (Cephalexin) a Highly Bioavailable Oral Antibiotic?

Yes, cephalexin is a highly bioavailable oral antibiotic with near-complete absorption from the gastrointestinal tract.

Pharmacokinetic Evidence of High Bioavailability

  • Cephalexin achieves 90–100% urinary recovery of the administered dose within 6–8 hours, indicating near-complete oral absorption. 1

  • The drug is totally and rapidly absorbed in the upper intestine, not from the stomach, which contributes to its high bioavailability and minimal gastrointestinal disturbance. 1

  • Peak serum concentrations are achieved predictably 2 hours after oral administration, with mean levels of 12.0 ± 0.8 mcg/mL following a single 500 mg dose in healthy adults. 2

  • A 250 mg oral dose produces mean peak serum concentrations of 7.7 mcg/mL, while a 500 mg dose achieves 12.3 mcg/mL, demonstrating dose-proportional pharmacokinetics consistent with reliable absorption. 3

  • Food does not interfere with cephalexin absorption, further supporting its robust oral bioavailability in clinical practice. 3

Clinical Implications of High Bioavailability

  • The high and predictable absorption allows cephalexin to be administered in relatively high oral doses (up to 4 grams daily in divided doses) without gastrointestinal irritation. 1

  • Because cephalexin is absorbed high in the intestinal tract, it does not disturb lower bowel flora, reducing the risk of antibiotic-associated diarrhea compared to agents absorbed more distally. 1

  • Urinary concentrations of 500–1,000 mcg/mL follow 250–500 mg oral doses, levels many times greater than the minimum inhibitory concentration for common urinary pathogens, making oral therapy highly effective for UTIs. 1

  • The mean peak serum concentration after a 500 mg oral dose (12.3 mcg/mL) is adequate to inhibit all group A streptococci, Streptococcus pneumoniae, and Staphylococcus aureus, as well as 85% of E. coli strains. 3

Factors Affecting Bioavailability

  • Probenecid enhances both peak serum concentration and duration of antibiotic activity by blocking renal tubular secretion, though this is rarely used clinically. 3

  • In children, higher doses per kilogram may be needed compared to adults due to greater body water turnover, but absorption remains complete and predictable. 1

  • Renal impairment significantly prolongs serum half-life (from 1.03 hours in normal subjects to 8.47 hours in anuric patients) but does not reduce absorption; dose adjustment is based on creatinine clearance, not bioavailability concerns. 2

Comparison to Other Oral Cephalosporins

  • A systematic review of cephalexin pharmacokinetics confirms dose-proportional increases in AUC₀₋∞ and Cmax across multiple studies, validating its consistent high bioavailability. 4

  • In patients with renal impairment, cephalexin's Cmax was recorded to be 0.5-fold higher than cefaclor, suggesting superior or equivalent absorption characteristics. 4

Common Pitfalls

  • Do not assume that high bioavailability means cephalexin penetrates all tissues equally; it does not enter host tissue cells, spinal fluid, or aqueous humor, which accounts for its low side-effect profile but limits use in CNS or intracellular infections. 1

  • Despite excellent oral absorption, cephalexin has a short serum half-life (approximately 1 hour in normal renal function), necessitating dosing every 6 hours (four times daily) to maintain therapeutic concentrations for serious infections. 2, 5

  • Twice-daily or thrice-daily dosing regimens are sometimes prescribed to improve adherence, but these require higher per-dose amounts (22–45 mg/kg BID or 15–25 mg/kg TID for pediatric MSSA infections with MIC 1–2 mg/L) to compensate for the short half-life. 5

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.